

Vincent Javaugue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3160066/publications.pdf>

Version: 2024-02-01

33
papers

1,023
citations

516681

16
h-index

434170

31
g-index

37
all docs

37
docs citations

37
times ranked

1020
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. <i>Blood</i> , 2017, 129, 1437-1447.	1.4	120
2	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. <i>Kidney International</i> , 2015, 88, 1135-1143.	5.2	104
3	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. <i>Blood</i> , 2019, 133, 576-587.	1.4	78
4	Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients. <i>American Journal of Kidney Diseases</i> , 2013, 62, 679-690.	1.9	75
5	Kidney Diseases Associated With Monoclonal Immunoglobulin M-secreting B-Cell Lymphoproliferative Disorders: A Case Series of 35 Patients. <i>American Journal of Kidney Diseases</i> , 2015, 66, 756-767.	1.9	68
6	Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. <i>Kidney International</i> , 2017, 91, 423-434.	5.2	66
7	Impaired Lysosomal Function Underlies Monoclonal Light Chain-associated Renal Fanconi Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2049-2061.	6.1	52
8	Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 64-72.	0.7	46
9	The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. <i>Kidney International</i> , 2017, 91, 720-728.	5.2	43
10	Animal models of monoclonal immunoglobulin-related renal diseases. <i>Nature Reviews Nephrology</i> , 2018, 14, 246-264.	9.6	43
11	A mouse model recapitulating human monoclonal heavy chain deposition disease evidences the relevance of proteasome inhibitor therapy. <i>Blood</i> , 2015, 126, 757-765.	1.4	36
12	Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 208-215.	0.7	34
13	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. <i>Kidney International</i> , 2020, 97, 589-601.	5.2	32
14	Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. <i>Blood</i> , 2020, 135, 1750-1758.	1.4	29
15	Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. <i>Cancers</i> , 2020, 12, 2885.	3.7	23
16	Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy. <i>Kidney International</i> , 2021, 99, 421-430.	5.2	18
17	Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. <i>Frontiers in Physiology</i> , 2017, 8, 149.	2.8	17
18	Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort. <i>Diabetologia</i> , 2020, 63, 915-923.	6.3	17

#	ARTICLE	IF	CITATIONS
19	Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders. <i>Kidney International</i> , 2019, 96, 94-103.	5.2	16
20	Heavy Chain Fibrillary Glomerulonephritis: A Case Report. <i>American Journal of Kidney Diseases</i> , 2019, 74, 276-280.	1.9	16
21	Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study. <i>Transplant International</i> , 2016, 29, 23-33.	1.6	12
22	RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance. <i>Kidney International</i> , 2022, 101, 331-337.	5.2	11
23	New clinical forms of hereditary apoA-I amyloidosis entail both glomerular and retinal amyloidosis. <i>Kidney International</i> , 2020, 98, 195-208.	5.2	10
24	Comprehensive molecular characterization of a heavy chain deposition disease case. <i>Haematologica</i> , 2018, 103, e557-e560.	3.5	8
25	Immunoglobulin light chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease. <i>Blood</i> , 2020, 136, 1645-1656.	1.4	7
26	Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor. <i>Kidney International Reports</i> , 2022, 7, 1913-1916.	0.8	6
27	The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. <i>Kidney International</i> , 2022, 102, 382-394.	5.2	6
28	Carfilzomib weekly 20/56 mg/m ² , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E17-E20.	4.1	5
29	Randall-Type Monoclonal Immunoglobulin Deposition Disease: New Insights into the Pathogenesis, Diagnosis and Management. <i>Diagnostics</i> , 2021, 11, 420.	2.6	4
30	Acute Renal Colic Due to Immunoglobulin Free Light Chain Kidney Stones: A Case Report of an Unusual Complication of Multiple Myeloma. <i>American Journal of Kidney Diseases</i> , 2019, 74, 700-702.	1.9	3
31	Carfilzomib weekly 20/56mg/m ² , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8017-8017.	1.6	1
32	Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1199-1202.	0.7	0
33	Chronic HCV Infection and Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2018, 132, 5632-5632.	1.4	0